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Chronic urticaria (CU) has a widespread spectrum on causal or exacerbating factors, clinical manifestations,
therapeutic response and quality of life affectation. Registries are useful tools in several real-life diagnosis and
management approach.
We aimed to evaluate the characteristics of CU patients living in Latin America through an original cross-
sectional registry with data entered by regional allergologists.
Results: Three hundred patients were included, being 72% female, with median age of 36 years (1–85) and 20
months of CU median evolution time. The cause of CU was reported as unknown in 72% of them.
Thirty-nine percent of suspected cases presented positive serology for Mycoplasma, positive autologous serum
skin test (ASST) was reported in 47%, and occasional presence of thyroid or antinuclear autoantibodies and
parasites. The impact of pruritus in their quality of life was moderate to severe in 60% of patients, with almost 3
out of four patients having partial or lack of urticaria control with anti-histamines.
Conclusions: Our registry provides retrospective data on the real-life assistance of a large number of patients from
the region. Continuous search for associated conditions and better treatment possibilities are needed, in order to
control the significant impact on quality of life and the length of disease.Introduction
Medical research has shown a huge development in the last decades,
particularly based on randomized clinical trials where safety and efficacy
of interventions have been objectively demonstrated. However, when the
ideal conditions established for efficacy trials intersect with real-world
effectiveness evaluations, a gap of information emerges, creating a real
need for practicing physicians.
There is also a need for non-interventional data, contributing toom, mgomez@fundacionayre.org
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certain disease, including cost-effectiveness interventions and quality of
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Registries provide information on several real-life procedures such as
diagnosis and management approach or validating outcomes.1 The
quality of evidence a registry could provide has been properly discussed
by Dreyer and Garner in the Journal of the American Medical Association
(JAMA), reporting on the Agency for Healthcare Research and Quality
definition of a registry as “an organized system that uses observational study
methods to collect uniform data (clinical and other) to evaluate specified.ar (R.M. Gomez), edgardo.jares@gmail.com (E. Jares), sanchezbmario@gmail.
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Abbreviations:
ANA Anti Nuclear Antibodies
Anti-H1 Anti Histamine 1
ASST autologous serum skin test
CU Chronic urticaria
CU-Q2oL: Chronic Urticaria Quality of life Questionnaire
CUR Chronic Urticaria Registry
CURE Chronic Urticaria Registry (www.urticaria-registry.com)
ESR Eritro Sedimentation Rate
HBV Hepatitis B Virus
HIV Human Immunodeficiency Virus





PROs Patients Reported Outcomes
SLaai Latin American Society of Allergy, Asthma &
Immunology
UAS7 Urticaria Activity Score in 7 days
VDRL Venereal Disease Research Laboratory
Table 1
Results of complementary tests from 300 patients reported. From this total, the
number of patients evaluated on each variable is detailed as N.
Variable Results
Median evolution in months (range). N ¼ 300 20,5 (1,5–552)
Median serum IgE in KU/L (range). N ¼ 139 144 (1–3245)
Mean eosinophils in % (range). N ¼ 263 2,96 (1–20)
Elevated C Reactive Protein in %. N ¼ 132 32
Positive D Dimer in %. N ¼ 8 62,5
Positive Anti TPO in %. N ¼ 130 9,2
Positive Autologous Serum Skin Test (ASST) in %. N ¼ 87 47,1
Positive ANA in %. N ¼ 114 10,5
Positive VDRL in %. N ¼ 103 1
Positive HIV in %. N ¼ 65 1,5
Positive Helicobacter pylori in %. N ¼ 43 11,6
Positive Mycoplasma in %. N ¼ 33 39,4
Positive HBV in %. N ¼ 77 2,6
Positive Parasites in %. N ¼ 159 8,8
Positive Ice test in %. N ¼ 106 10,4
Positive Vibration test in %. N ¼ 58 0
Positive Local Heat test in %. N ¼ 14 21,4
Positive Pressure test in %. N ¼ 137 21,9
R.M. Gomez et al. World Allergy Organization Journal 12 (2019) 100042outcomes for a population defined by a particular disease, condition or
exposure, and that serves a predetermined scientific, clinical or policy
purpose(s)”.2
Chronic urticaria is a mast cell driven disease, characterized by the
recurrence of wheals, angioedema or both, lasting more than 6 weeks. It
impairs quality of life at different levels, and as more is learned regarding
the pathogenesis of this chronic condition, there is a need for continual
updating of guidelines.3 The heterogeneity in clinical presentation,
elicitors and/or causes, therapeutic response and level of quality of life
impairment, complicate our ability to develop standardized strategies for
the diagnostic and therapeutic approach of this chronic disease.
Based on the above mentioned considerations, members of two
Argentinian scientific organizations devoted to research in allergic dis-
eases developed and provided an electronic platform to the Latin
American Society of Allergy, Asthma & Immunology (SLaai) for a
Chronic Urticaria Registry (CUR). Its characteristics have been previously
extensively described and published.4 Briefly, allergists from Spanish and
Portuguese speaking countries from Latin America registered their cases
of chronic urticaria in a retrospective and anonymous manner providing
data on demographics, duration of disease, precipitating factors, evalu-
ations performed, validated quality-of-life parameters and treatment
response.
Based on previous explanations, here we report on the remarkable
findings from a registry of a large sample of patients, potentially
providing clues for its approach and management.
Methods
Verified Latin American private and/or public allergologists accessed
this restricted online registry through the web page of SLaai and entered
anonymous data of patients with chronic urticaria (CU).
Having the classical signs and symptoms for over 6 weeks regardless
of cause or provoking factor or previous treatment were the main in-
clusion criteria; any age or sex was accepted. The background of having
had incomplete or temporal control with anti-histamines and controlled
co-morbidities was also considered.
Exclusion criteria for registering a case consisted of a change in ur-
ticaria condition when co-morbidities were controlled, or complete
remission of urticaria when avoiding the identified provoking factors
(such as exclusively induced urticaria).2
The data requested consisted of age, sex and length of disease by the
time of collection of data and identified causes by patients and/or phy-
sicians. Also recorded were diagnostic procedures and evaluations per-
formed, laboratory data, treatment received and response. Patient
Reported Outcomes (PROs) were evaluated by mean of two validated
tools: Urticaria Activity Score in 7 days (UAS7), to evaluate disease ac-
tivity, and Chronic Urticaria Quality of life Questionnaire (CU-Q2oL), to
assess Health Related Quality of Life (HRQoL).5–7
No written consent was required for this observational retrospective
study, registering data from the usual management of these patients in an
anonymous way by verified physicians.8 Notwithstanding, two inde-
pendent ethics committees were consulted (Medical Council of Salta and
Clinical Studies Foundation of Buenos Aires, Argentina); they agreed on
this statement, and one of them suggested informing the patient of the
initiative and the anonymous feature of the registry if this particular
patient assistance was requested again by the reporting physician. This
was stated on the web page at the beginning of the registry form.
Descriptive statistics are presented, with frequencies of reported data,
comparisons between groups by contingency tables and Yate's x2 for the
probabilities of a positive test (Interactive Statistical Calculation Pages at
www.statpages.info).
Results
At the point when 300 patients had been included (July 2015–May
2018), the authors decided to analyze the collected data. Seventy two
percent of patients were female, with a mean age of 36,43 years (age
range 1–85).
The list of countries from the region and the participating proportion
included: Brazil with 32.3% of reports, followed by Argentina 28%,
Venezuela 16.3%, Mexico 9.7%, Dominican Republic 7.7%, Ecuador 3%,
Paraguay 1%, and Peru 0.6% as well as Bolivia, Chile, Colombia and
Cuba with 0.3% of reports.
The proportion of patients with identified causal agents, yet
remaining with urticaria was 28%.
The main results of complementary tests are reported in Table 1.
There is no single consensus on CU approach on diagnosis and man-
agement.3 Then, total cases for each specific performed test were
described in the first row, and positive cases in the next.
From this description, even in a small number of patients we found a
high frequency of elevated D dimer. In order to elucidate a statistical
difference, a comparison of proportions instead of absolute numbers was
performed (62.5% positive vs 37.5% negative), resulting in a significant
value of p < 0.0001. It also evidenced an Odds Ratio: (OR) ¼ 8 (95%CI
Fig. 2. Level of anxiety feeling associated to chronic urticaria in last 15 days,
reported on CU-Q2oL questionnaire.
Fig. 3. Efficacy of anti-histamines taken for urticaria control.
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angioedema and poor response to AntiH1 antihistamines at double doses.
Among patients reported by their physicians has having a potential
identified cause, none of them had physical triggers: in almost 30% (24
patients out of 85) urticaria was associated with drugs (2 patients) as well
as with infections (10 cases, reporting 5 with Helicobacter pilory, 2 with
sinusitis and 3 with genitourinary infections), hypothyroidism (8 cases),
stress and chronic gastritis (2 patients each) and food and cryoglobulins
(1 patient each). There were 3 patients presenting positive tests for in-
fectious diseases (Cyto Megalo Virus, Ebstein Barr Virus and Staphylo-
coccus in the pharynx), but they were not considered to have a causal role
according to the reporting physician's criteria.
Besides, 43.7% of patients having autologous serum test: ASSTþ (38
from a total of 87 ASSTþ) were reported as having autoimmune urticaria
as the probable cause (p < 0.0001). ASST was positive in 4 out of 6
hypothyroid patients, but antibodies to thyroid peroxidase were found in
9,2% of the patients evaluated for it.
Surprisingly for an endemic region, parasites were found in less than
9% of the samples obtained, having being searched for in around half of
the total sample.
Many patients reported with an identified cause (plausible to be an
inducible urticaria), had negative tests (pressure, ice, vibration, heat): 21
þ out of 85 (almost 25%). When compared with those reported as un-
known causes, there were no significant differences (p ¼ 0.177).
Data collected from PROs questionnaires showed that 35% of them
presented more than 20 wheals, and a larger proportion of 52% had
moderate to severe pruritus in UAS7 evaluation. Sixty percent of patients
reported having moderate to unbearable pruritus, and 40% presented
moderate to unbearable anxiety because of it in CU-Q2oL evaluations
(Figs. 1 and 2).
When analyzing representative PROs variables, the mean value of
pruritus and the presence of wheals were indicative of a moderate in-
tensity (2.896 points in 1–5 scale), while the mean affectation of sleep,
social relationships and work was just over a little (2.15, 2.11 and 2.22
respectively).
Twenty-eight percent of patients had no concomitant angioedema.
On efficacy evaluation of treatment, more than half of patients (61%)
had incomplete response to anti-histamines and 10% had no improve-
ment at all. Only 13% could achieve complete control of urticaria with
licensed doses of Anti-H1 (Fig. 3).
A descriptive figure with frequencies of treatment provided is shown,
where cetirizine was the first choice in almost half of patients, followed
by fexofenadine in less than 20% (Fig. 4).
Discussion
The highly relevant value of a registry has been described on intro-
duction, and to our knowledge this is the first publication of data from a
chronic urticaria registry. There is a well-known initiative on the topic,
the Chronic Urticaria Registry (CURE at http://www.urticaria-regist
ry.com), which would certainly provide additional data on this chronicFig. 1. Impact of Pruritus in the last 15 days, according to validated Quality of
Life in Chronic Urticaria questionnaire (CU-Q2oL).
3
condition and particularly on topics that go beyond our present objec-
tives, such as activity and daily impact during the course of disease as
well as the attributable health care costs. Our registry provides retro-
spective data on the real-life assistance of a large number of patients,
with a chronic and infrequent condition in the general population, and
not of clinical trials or a new intervention under evaluation. This pecu-
liarity allows us to offer an overview of the actual situation of these pa-
tients and how they are addressed and treated in daily life in this region.
Our population with 3 out of 4 female patients below 40 years old is
not different from previous reports on the topic, and even from pre-
dominant age and sex in a smaller Ecuadorian sample.9 Surprisingly,
coincidentally with this comparison, the median time of evolution of
urticaria by the time of assessment in our registry was also above 16
weeks. Even being considered as a chronic condition from 6 weeks on-
wards, this data about evolution of the entity by the time it is reported in
different assessments is far longer, probably suggesting that control of
urticaria is not achieved around the moment the diagnosis has been
made.
The Latin American region tends to be considered historically as
endemic for parasites.10 However, only in half of patients parasites were
searched for and found in less than 10%. A correlation with eosinophilia
was considered, but the mean percentage in almost the total sample was
below 3%.
Multiple infections were associated with chronic urticaria.11,12 From
results shown in Table 1, there were minimal frequencies of association
with viral infections like hepatitis and HIV, or H. pylori infection; there
was a remarkable frequency of Mycoplasma spp IgG positive test in one
third of tested patients. A similar prevalence of 30% of IgM anti Myco-
plasma pneumonia in acute urticaria, and just 7% in chronic condition,
was reported in patients from Singapore, but its role in chronic urticaria
remains uncertain13. We have previously reported 2 patients having
Treponema infection and chronic urticaria, which faded out when proper
antibiotics were given.14 The importance of Helicobacter pylori presence
remains controversial in CU.12
Autoimmune factors seem to have a major role in CU, and ASST has
been considered an in vivomarker of auto-reactivity. Generally, a positive
reaction indicates the presence of IgG antibodies against either the high-
Fig. 4. First choice in prescription of anti-histamines for chronic urticaria treatment (from 288 reports).
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cases) or membrane-bound IgE (in a minority of patients), with the ca-
pacity of inducing basophils or mast cells activation and mediator
release. In agreement with a recent Egyptian evaluation and a revision on
the pathogenesis of CSU, we found that ASST was positive only in about
half of the patients evaluated, despite its severity or length of disease.15,
16 Not only IgG but also IgE autoantibodies could play a hypothetical role
both in the etiology and in pathogenesis of CSU in a subset of patients,
such as those having autoimmune thyroid disease, a situation that be-
sides its autoimmune nature, has been termed as “auto-allergic”.15,17,18
In the present report we did not have the chance to collect
autoantigen-specific IgE, then we found positive IgG
anti-thyroperoxidase antibodies in less than 10%, and also a similar
frequency of antinuclear antibodies. In a large population sample from
Israel where antinuclear antibodies were investigated because of auto-
immune related symptoms, almost 15% were positive for any Anti Nu-
clear Antibodies (ANA), and less than 5% presented chronic urticaria.19
An extended follow-up in such cases was suggested, since a significant
proportion of positive patients were diagnosed with an autoimmune
disease in a 10-year follow-up evaluation.20
It is speculated that physicians reporting in the present registry
consider autoimmunity as one of the identified causes in the reported
cases; another possible option of identified cause should be the inducing
factors in chronic inducible condition. Nonetheless, only a quarter of
physical tests were positive.
Another unidentified association with CU corresponds to the coagu-
lation system involvement. Tissue factor is over expressed in activated
eosinophils, and also eosinophilic mediators including tissue factor can
activate mast cells.15,21 The activation of the coagulation cascade may
reflect endothelial cell activation at least in a proportion of patients with
chronic urticaria, having elevated D-dimer and being associated,
together with other systemic inflammatory markers such as ESR and C
Reactive Protein, with higher severity and refractoriness to anti-H1
therapy.21,22 In the reduced number of our patients who underwent to
D-dimer determination, more than half presented elevated levels, and
those were associated to a higher frequency of concomitant angioedema4
and lack of control with antihistamines. Besides D-dimer, IL-6 and Lip-
ocalin 2 have been described as serum markers that potentially predict
therapeutic response.23
Regarding therapeutic response, our patients had complete control of
urticaria in response to licensed doses of antihistamines in less than 15%
of cases, and more than 60% had poor control. The more frequent ther-
apeutic option for our physicians was cetirizine, which is an over-the-
counter medication in many places, followed by fexofenadine. It should
be mentioned that here we do not have a frame based on the current
guidelines indication of a four-fold increase in dose,3 and most of our
reported cases used double doses and some antihistamine combinations.
For it these reasons, and because the registered report was done at initial
evaluations when diagnosing the patient, we only have a single report of
omalizumab treatment.
It is alsoworthwhile tonotice theHRQoL involvement at this evaluation
time,with 60%of patients havingmoderate to severe symptoms and almost
half of them presenting extreme anxiety. In the present registry, both vali-
dated UAS7 and CU-Q2oL tools have been considered (not all variables
included from last one, selected at authors' criteria).24,25 The significant
impactofCUinqualityof lifehasbeenrepeatedlydescribed,3,26 anda recent
evaluation in a Latin American population from Mexico demonstrated (in
coincidence with our results) that pruritus is perhaps the most representa-
tive problem, with sleep, social relationships and work also affected.27
No discrimination, neither about private and public assistance nor
socio-economic status, was requested on the questionnaire. As a conse-
quence, the impact of these conditions in the evaluated population
cannot be inferred.
Conclusions
This analysis of a representative sample of Latin American CU pa-
tients provides an overview of the situation of those patients, both for the
assisting allergists and for health authorities.
The magnitude of this affectation deserves special attention in order
to alert physicians, but also to help patients to achieve urticaria control
and improve their affected quality of life.
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